A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification

This study has been completed.
Sponsor:
Collaborator:
Allergan
Information provided by (Responsible Party):
Frank A. Bucci, Jr., M.D., Bucci Laser Vision Institute
ClinicalTrials.gov Identifier:
NCT01021761
First received: November 25, 2009
Last updated: August 26, 2011
Last verified: August 2011
Results First Received: May 25, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Pharmacokinetics/Dynamics Study;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Outcomes Assessor);   Primary Purpose: Treatment
Condition: Cataracts
Interventions: Drug: Ketorolac Tromethamine
Drug: Bromfenac
Drug: nepafenac

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Xibrom Xibrom to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
Nevanac Nevanac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
Acuvail Acuvail to be given preoperatively. One drop BID, 1 day pre op and day of surgery 3 doses prior to surgery.

Participant Flow:   Overall Study
    Xibrom     Nevanac     Acuvail  
STARTED     42     42     42  
COMPLETED     41     38     42  
NOT COMPLETED     1     4     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Xibrom Xibrom to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
Nevanac Nevanac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
Acuvail Acuvail to be given preoperatively. One drop BID, 1 day pre op and day of surgery 3 doses prior to surgery.
Total Total of all reporting groups

Baseline Measures
    Xibrom     Nevanac     Acuvail     Total  
Number of Participants  
[units: participants]
  42     42     42     126  
Age  
[units: participants]
       
<=18 years     0     0     0     0  
Between 18 and 65 years     18     15     21     54  
>=65 years     24     27     21     72  
Age  
[units: years]
Mean ± Standard Deviation
  72  ± 31     74  ± 29     75  ± 30     74  ± 29  
Gender  
[units: participants]
       
Female     26     29     26     81  
Male     16     13     16     45  
Region of Enrollment  
[units: participants]
       
United States     42     42     42     126  



  Outcome Measures

1.  Primary:   Aqueous PGE2 Inhibition   [ Time Frame: Day 4 of treatment ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Frank A. Bucci, Jr., MD
Organization: Bucci Laser Vision
phone: 570-825-5949
e-mail: Buccivision@aol.com


No publications provided


Responsible Party: Frank A. Bucci, Jr., M.D., Bucci Laser Vision Institute
ClinicalTrials.gov Identifier: NCT01021761     History of Changes
Other Study ID Numbers: 2009 0199
Study First Received: November 25, 2009
Results First Received: May 25, 2011
Last Updated: August 26, 2011
Health Authority: United States: Institutional Review Board